Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy

A range of new treatment options has recently become available for patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone is continued when performing chemotherapy or androgen deprivation with new...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Lett
Egile Nagusiak: von Klot, Christoph A., Kuczyk, Markus A., Boeker, Alena, Reuter, Christoph, Imkamp, Florian, Herrmann, Thomas R.W., Tezval, Hossein, Kramer, Mario W., Perner, Sven, Merseburger, Axel S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2017
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5244876/
https://ncbi.nlm.nih.gov/pubmed/28123517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.5392
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak